Back to Stakeholders
Research, Drug Development & ManufacturingLead program: Phase II

Clairvoyant Therapeutics

1 Drug Candidate

Clairvoyant Therapeutics is a Canadian clinical-stage biotech developing synthetic psilocybin for alcohol use disorder (AUD). The company ran a fully randomized, double-blinded Phase IIb multi-country trial in the EU and Canada enrolling 154 participants, with topline data anticipated in early 2025. Founded in 2021 in Vancouver, a proposed acquisition by Psyence Biomed (Nasdaq: PBM) for $500K in September 2024 fell through following due diligence.

Drug Pipeline

1

Psilocybin (synthetic)

Psilocybin
Phase II
Alcohol Use Disorder (AUD)

Phase IIb randomized, double-blind, multi-country trial (EU + Canada); 154 participants; topline data expected early 2025.

Quick Facts

Type
Private Biotech
Founded
2021
Lead Stage
Phase II
Website
Visit